- $910.44m
- $408.14m
- $24.05m
U.S. STOCKS ON THE MOVE-United Airlines Holdings, Energy companies, Tesla
U.S. STOCKS ON THE MOVE-Shake Shack, Arrowhead Pharmaceuticals, Lockheed Martin
U.S. STOCKS ON THE MOVE-Alkermes, Ball Corp, NovaBridge
Alumis' skin disease drug meets main goal in late-stage trials; shares surge (updated)
NASDAQ RESUMED AT 07:35 AM
Alumis jumps after skin disease drug meets main goal in late-stage trials
Alumis skin disease drug meets main goal of two late-stage trials
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Brief: Alumis Inc - Co & Its Unit Issues Notice Of Material Breach & Notification Of Claim For Indemnification To Climb Bio - SEC Filing
Biopharmaceutical firm Alumis's Q3 net loss widens
Brief: Alumis Q3 Operating Expenses USD 117.358 Million
Alumis Inc reports results for the quarter ended June 30 - Earnings Summary
Alumis Inc expected to post a loss of $1.38 a share - Earnings Preview
Brief: Alumis Files For Mixed Shelf Offering Of Up To $400 Mln
Brief: Alumis Stockholders Approve Merger With Acelyrin
Brief: Alumis And Acelyrin Announce Amended Merger Agreement
U.S. STOCKS ON THE MOVE-Affirm, Trump Media, Comstock
Alumis jumps on licensing deal for skin drug
Brief: Alumis And Kaken Pharmaceutical Announce Collaboration And Licensing Agreement For ESK-001 In Dermatology In Japan